AMGN vs XNCR
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. XNCR: Xencor is a clinical-stage biopharma using proprietary protein engineering to develop next-generation bispecific antibodies for cancer and autoimmune conditions.
Side-by-side fundamentals
| Metric | AMGN | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $385.16 | $20.21 | |
| Market cap as of 2026-08-03 | $207.9B | $1.5B | |
| P/E as of 2026-08-03 | 26.78 | n/a | |
| PEG as of 2026-08-03 | 5.48 | n/a | |
| Net margin as of 2026-08-03 | +21.0% | -177.1% | AMGN higher |
| Gross margin as of 2026-08-03 | +74.0% | n/a | |
| Operating margin as of 2026-08-03 | +28.8% | -222.4% | AMGN higher |
| ROE as of 2026-08-03 | +89.4% | -28.8% | AMGN higher |
| ROA as of 2026-08-03 | +8.6% | -20.5% | AMGN higher |
| Debt / equity as of 2026-08-03 | 6.24 | 0.21 | XNCR lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.1% | -25.4% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | -8.6% | AMGN higher |
| Dividend yield as of 2026-08-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.43 | 1.51 | |
| 1-year return as of 2026-07-31 close | +30.5% | +142.9% | XNCR higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.